Pharmaceutical Executive November 17, 2022
Girisha Fernando

New regulations may require regulators to explore new payment options.

Few issues raise the ire of Americans more than the high cost of prescription drugs–and the Biden administration is seeking to tackle the issue through provisions in the recently passed Inflation Reduction Act. According to advocates, the law offers an effective way to begin the process of curbing high drug prices, thus making medical care more available and reducing costs to society. According to opponents, the new rules will harm innovation, with hundreds of potential treatments and cures left on the table because companies will have no financial incentive to pursue them.

That puts the government, the medical industry, and patients between a rock and a hard place: Cutting costs...

Today's Sponsors

Transcarent
SalesSparx

Today's Sponsor

Health Edge

 
Topics: Biotechnology, Insurance, Medicare, Payment Models, Pharma, Pharma / Biotech, Value Based
Top Healthcare Industry Facts for 2023
Inflation Reduction Act Could Cut Medicare Drug Spending by 5%, Study Suggests
States with the largest dual-eligible populations
Smoothing Medicare Part D Out-Of-Pocket Costs Under The Inflation Reduction Act
CMS proposes universal quality measures across all programs

Share This Article